Top

Published in:

01-01-2016 | Review

The role of cullin proteins in gastric cancer

Authors: Peng Chen, Guo-Dong Yao

Published in: Tumor Biology | Issue 1/2016

Abstract

The cullin proteins are a family of scaffolding proteins that associate with RING proteins and ubiquitin E3 ligases and mediate substrate–receptor bindings. Thus, cullin proteins regulate the specificity of ubiquitin targeting in the regulation of proteins involved in various cellular processes, including proliferation, differentiation, and apoptosis. There are seven cullin proteins that have been identified in eukaryotes: CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, and CUL7/p53-associated parkin-like cytoplasmic protein. All of these proteins contain a conserved cullin homology domain that binds to RING box proteins. Cullin–RING ubiquitin ligase complexes are activated upon post-translational modification by neural precursor cell-expressed, developmentally downregulated protein 8. The aberrant expression of several cullin proteins has been implicated in many cancers though the significance in gastric cancer has been less well investigated. This review provides the first systematic discussion of the associations between all members of the cullin protein family and gastric cancer. Functional and regulatory mechanisms of cullin proteins in gastric carcinoma progression are also summarized along with a discussion concerning future research areas. Accumulating evidence suggests a critical role of cullin proteins in tumorigenesis, and a better understanding of the function of these individual cullin proteins and their targets will help identify potential biomarkers and therapeutic targets.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.PubMed

Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17:4421–8. doi:10.3748/wjg.v17.i39.4421.PubMedPubMedCentral

Fang WL, Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, et al. The risk factors of lymph node metastasis in early gastric cancer. Pathol Onocl Res. 2015. doi:10.1007/s12253-015-9920-0.

Coburn NG, Lourenco LG, Rossi SE, Gunraj N, Mahar AL, Helyer LK, et al. Management of gastric cancer in Ontario. J Surg Oncol. 2010;102:54–63. doi:10.1002/jso.21561.PubMed

Chen Y, Awan N, Haveman JW, Apostolou C, Chang DK, Merrett ND. Gastric cancer: Australian outcomes of multi-modality treatment with curative intent. ANZ J Surg. 2014. doi:10.1111/ans.12693.

Voutsadakis IA. The ubiquitin-proteasome system and signal transduction pathways regulating epithelial mesenchymal transition of cancer. J Biomed Sci. 2012;19:67. doi:10.1186/1423-0127-19-67.PubMedPubMedCentral

Liu J, Nussinov R. The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: conformational control of substrate orientation. PLoS Comput Biol. 2009;5, e1000527. doi:10.1371/journal.pcbi.1000527.PubMedPubMedCentral

Qi J, Kim H, Scortegagna M, Ronai ZA. Regulators and effectors of Siah ubiquitin ligases. Cell Biochem Biophys. 2013;67:15–24. doi:10.1007/s12013-013-9636-2.PubMedPubMedCentral

Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell Biol. 2009;33:275–86. doi:10.1016/j.molcel.2009.01.014.

10.

Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. ‘protein modifications: beyond the usual suspects’ review series. EMBO Rep. 2008;9:536–42. doi:10.1038/embor.2008.93.PubMedPubMedCentral

11.

Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains—from structures to functions. Nat Rev Mol Cell Biol. 2009;10:659–71. doi:10.1038/nrm2767.PubMed

12.

Ikeda F, Crosetto N, Dikic I. What determines the specificity and outcomes of ubiquitin signaling? Cell. 2010;143:677–81. doi:10.1016/j.cell.2010.10.026.PubMed

13.

Sadowski M, Suryadinata R, Tan AR, Roesley SN, Sarcevic B. Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. IUBMB Life. 2012;64:136–42. doi:10.1002/iub.589.PubMed

14.

Sekiyama N, Jee J, Isogai S, Akagi K, Huang TH, Ariyoshi M, et al. NMR analysis of Lys63-linked polyubiquitin recognition by the tandem ubiquitin-interacting motifs of Rap80. J Biomol NMR. 2012;52:339–50. doi:10.1007/s10858-012-9614-9.PubMed

15.

Hofmann K. Ubiquitin-binding domains and their role in the DNA damage response. DNA Repair (Amst). 2009;8:544–56. doi:10.1016/j.dnarep.2009.01.003.

16.

Jin L, Williamson A, Banerjee S, Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell. 2008;133:653–65. doi:10.1016/j.cell.2008.04.012.PubMedPubMedCentral

17.

Kravtsova-Ivantsiv Y, Sommer T, Ciechanover A. The lysine48-based polyubiquitin chain proteasomal signal: not a single child anymore. Angew Chem Int Ed Engl. 2013;52:192–8. doi:10.1002/anie.201205656.PubMed

18.

Lee EK, Diehl JA. SCFs in the new millennium. Oncogene. 2014;33:2011–8. doi:10.1038/onc.2013.144].PubMed

19.

Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans. 2009;37(Pt 5):937–53. doi:10.1042/BST0370937].PubMed

20.

Pan Y, Xu H, Liu R, Jia L. Induction of cell senescence by targeting to Cullin-RING Ligases (CRLs) for effective cancer therapy. Int J Biochem Mol Biol. 2012;3:273–81.PubMedPubMedCentral

21.

Lu A, Pfeffer SR. A CULLINary ride across the secretory pathway: more than just secretion. Trends Cell Biol. 2014;24(7):389–99. doi:10.1016/j.tcb2014.02.011.PubMedPubMedCentral

22.

Zimmerman ES, Schulman BA, Zheng N. Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol. 2010;20:714–21. doi:10.1016/j.sbi.2010.08.010.PubMedPubMedCentral

23.

Lee J, Zhou P. Cullins and cancer. Genes Cancer. 2010;1:690–9. doi:10.1177/1947601910382899.PubMedPubMedCentral

24.

Sarikas A, Hartmann T, Pan ZQ. The cullin protein family. Genome Biol. 2011;12:220. doi:10.1186/gb-2011-12-4-220.PubMedPubMedCentral

25.

Watson IR, Irwin MS, Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. Cancer Cell. 2011;19:168–76. doi:10.1016/j.ccr.2011.01.002.PubMed

26.

Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20. doi:10.1038/nrm1547.PubMed

27.

Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 2002;416:703–9. doi:10.1038/416703a.PubMed

28.

Xie CM, Wei W, Sun Y. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics. 2013;40:97–106. doi:10.1016/j.jgg.2013.02.001.PubMed

29.

Wang W, Chen Y, Deng J, Zhou J, Gu X, Tang Y, et al. Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer. J Cancer Res Clin Oncol. 2015. doi:10.1007/s00432-015-1931-4.

30.

Skaar JR, D’Angiolella V, Pagan JK, Pagano M. SnapShot: F box proteins II. Cell. 2009;137:1358. doi:10.1016/j.cell.2009.05.040. 1358 e1351.PubMed

31.

Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14:369–81. doi:10.1038/nrm3582.PubMed

32.

Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14:233–47. doi:10.1038/nrc3700].PubMedPubMedCentral

33.

Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009;69:3788–94. doi:10.1158/0008-5472.CAN-08-2846].PubMed

34.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67:9006–12. doi:10.1158/0008-5472.CAN-07-1320].PubMed

35.

Milne AN, Leguit R, Corver WE, Morsink FH, Polak M, de Leng WW, et al. Loss of CDC4/FBXW7 in gastric carcinoma. Cell Oncol. 2010;32:347–59. doi:10.3233/CLO-2010-523].PubMedPubMedCentral

36.

Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 2013;13:141. doi:10.1186/1471-230X-13-141.PubMedPubMedCentral

37.

Cho HJ, Oh YJ, Kwon J, Kwon JY, Kim KS, Kim H. c-Myc stimulates cell invasion by inhibiting FBX8 function. Mol Cells. 2010;30:355–62. doi:10.1007/s10059-010-0134-8.PubMed

38.

Wu P, Wang F, Wang Y, Men H, Zhu X, He G, et al. Significance of FBX8 in progression of gastric cancer. Exp Mol Pathol. 2015;98:360–6. doi:10.1016/j.yexmp.2015.03.015.PubMed

39.

Yano H, Kobayashi I, Onodera Y, Luton F, Franco M, Mazaki Y, et al. Fbx8 makes Arf6 refractory to function via ubiquitination. Mol Biol Cell. 2008;19:822–32. doi:10.1091/mbc.E07-08-0763.PubMedPubMedCentral

40.

Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–81. doi:10.1038/nrc1881.PubMed

41.

Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010;464:374–9. doi:10.1038/nature08815.PubMedPubMedCentral

42.

Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, et al. Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta. 1825;2012:11–7. doi:10.1016/j.bbcan.2011.09.002.

43.

Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J, et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice. Nat Genet. 2010;42:83–8. doi:10.1038/ng.498.PubMed

44.

Wei Z, Jiang X, Liu F, Qiao H, Zhou B, Zhai B, et al. Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumour Biol. 2013;34:181–92. doi:10.1007/s13277-012-0527-8.PubMed

45.

Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, et al. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011;42:375–83. doi:10.1016/j.humpath.2010.09.003.PubMed

46.

Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res. 2007;67:2480–9. doi:10.1158/0008-5472.CAN-06-3021.PubMed

47.

Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res. 2009;15:173–81. doi:10.1007/s12253-008-9120-2.PubMed

48.

Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C. cDNA cloning and expression analysis of new members of the mammalian F-box protein family. Genomics. 2000;67:40–7. doi:10.1006/geno.2000.6211.PubMed

49.

Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 2009;35:442–53. doi:10.1016/j.molcel.2009.06.030.PubMedPubMedCentral

50.

Zhang L, Hou Y, Wang M, Wu B, Li N. A study on the functions of ubiquitin metabolic system related gene FBG2 in gastric cancer cell line. J Exp Clin Cancer Res. 2009;28:78. doi:10.1186/1756-9966-28-78.PubMedPubMedCentral

51.

Moroishi T, Nishiyama M, Takeda Y, Iwai K, Nakayama KI. The FBXL5-IRP2 axis is integral to control of iron metabolism in vivo. Cell Metab. 2011;14:339–51. doi:10.1016/j.cmet.2011.07.011.PubMed

52.

Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science. 2009;326:718–21. doi:10.1126/science.1176333.PubMedPubMedCentral

53.

Salahudeen AA, Thompson JW, Ruiz JC, Ma HW, Kinch LN, Li Q, et al. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science. 2009;326:722–6. doi:10.1126/science.1176326.PubMedPubMedCentral

54.

Cen G, Ding HH, Liu B, Wu WD. FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration. Tumour Biol. 2014;35:8633–8. doi:10.1007/s13277-014-2104-9.PubMed

55.

MacGrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. J Cell Sci. 2012;125:1621–6. doi:10.1242/Jcs.093781.PubMedPubMedCentral

56.

Migita K, Takayama T, Matsumoto S, Wakatsuki K, Tanaka T, Ito M, et al. Prognostic impact of RING box protein-1 (RBX1) expression in gastric cancer. Gastric Cancer. 2014;17:601–9. doi:10.1007/s10120-013-0318-y.PubMed

57.

Ohta T, Michel JJ, Schottelius AJ, Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell. 1999;3:535–41.PubMed

58.

Skowyra D, Koepp DM, Kamura T, Conrad MN, Conaway RC, Conaway JW, et al. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science. 1999;284:662–5.PubMed

59.

Chen X, Wang Y, Zang W, Du Y, Li M, Zhao G. miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells. Tumour Biol. 2014;36:2393–401. doi:10.1007/s13277-014-2849-1.PubMed

60.

Kong Y, Kejun N, Yin Y. Identification and characterization of CAC1 as a novel CDK2-associated cullin. Cell Cycle. 2014;8:3552–61. doi:10.4161/cc.8.21.9955.

61.

Zheng Q, Zhao LY, Kong Y, Nan KJ, Yao Y, Liao ZJ. CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line. World J Surg Oncol. 2013;11:5. doi:10.1186/1477-7819-11-5.PubMedPubMedCentral

62.

Park SW, Chung NG, Hur SY, Kim HS, Yoo NJ, Lee SH. Mutational analysis of hypoxia-related genes HIF1alpha and CUL2 in common human cancers. APMIS. 2009;117:880–5. doi:10.1111/j.1600-0463.2009.02550.x.PubMed

63.

De Maio FA, Rocco CA, Aulicino PC, Bologna R, Mangano A, Sen L. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability. AIDS Res Hum Retroviruses. 2012;28:619–27. doi:10.1089/AID.2011.0291.PubMed

64.

Bulatov MEM, Chatterjee S, Knebel A, Shimamura S, Konijnenberg A, Johnson C, et al. Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2). J Biol Chem. 2015;290:4178–91. doi:10.1074/jbc.M114.616664.PubMed

65.

Mahrour N, Redwine WB, Florens L, Swanson SK, Martin-Brown S, Bradford WD, et al. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J Biol Chem. 2008;283:8005–13. doi:10.1074/jbc.M706987200.PubMed

66.

Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24:652–7. doi:10.1111/j.1440-1746.2008.05666.x.PubMed

67.

Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13:468–75. doi:10.1016/j.intimp.2012.05.016.PubMedPubMedCentral

68.

Kazi JU, Ronnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol. 2013;7:693–703. doi:10.1016/j.molonc.2013.02.020.PubMed

69.

Lai R-H, Hsiao Y-W, Wang M-J, Lin H-Y, Wu C-W, Chi C-W, et al. SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett. 2010;288:75–85. doi:10.1016/j.canlet.2009.06.025.PubMed

70.

Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, et al. Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol. 2015;141:443–52. doi:10.1007/s00432-014-1838-5.PubMed

71.

Furukawa M, He YJ, Borchers C, Xiong Y. Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat Cell Biol. 2003;5:1001–7. doi:10.1038/ncb1056.PubMed

72.

Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG. Sequence and structural analysis of BTB domain proteins. Genome Biol. 2005;6:R82. doi:10.1186/gb-2005-6-10-r82.PubMedPubMedCentral

73.

Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell. 2009;36:39–50. doi:10.1016/j.molcel.2009.09.022.PubMedPubMedCentral

74.

Merchant JL. Hedgehog signalling in gut development, physiology and cancer. J Physiol. 2012;590(Pt 3):421–32. doi:10.1113/jphysiol.2011.220681.PubMed

75.

Zeng C, Wang Y, Lu Q, Chen J, Zhang J, Liu T, et al. SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2014;33:75. doi:10.1186/s13046-014-0075-8.PubMedPubMedCentral

76.

Zeng Q, Zhang L, Wang B, Ou CY, Chien CT, Jiang J. A Hedgehog-induced BTB protein modulates Hedgehog signaling by degrading Ci/Gli transcription factor. Dev Cell. 2006;10:710–29. doi:10.1016/j.devcel.2006.05.004.

77.

Kim MS, Je EM, Oh JE, Yoo NJ, Lee SH. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers. APMIS. 2013;121:626–33. doi:10.1111/apm.12030.PubMed

78.

Lee J, Zhou P. Pathogenic role of the CRL4 ubiquitin ligase in human disease. Front Oncol. 2012;2:21. doi:10.3389/fonc.2012.00021.PubMedPubMedCentral

79.

Kerzendorfer C, Whibley A, Carpenter G, Outwin E, Chiang SC, Turner G, et al. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks. Hum Mol Genet. 2010;19:1324–34. doi:10.1093/hmg/ddq008.PubMedPubMedCentral

80.

Kerzendorfer C, Hart L, Colnaghi R, Carpenter G, Alcantara D, Outwin E, et al. CUL4B-deficiency in humans: understanding the clinical consequences of impaired Cullin 4-RING E3 ubiquitin ligase function. Mech Ageing Dev. 2011;132:366–73. doi:10.1016/j.mad.2011.02.003.PubMed

81.

Hannah J, Zhou PB. The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies. Chin J Cancer. 2013;32:478–82. doi:10.5732/cjc.012.10279.PubMedPubMedCentral

82.

Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, et al. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med. 2011;15:350–8. doi:10.1111/j.1582-4934.2009.00971.x.PubMed

83.

Xu Y, Wang Y, Ma G, Wang Q, Wei G. CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation. J Neurooncol. 2014;116:625–32. doi:10.1007/s11060-013-1349-2.PubMed

84.

Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74:520–31. doi:10.1158/0008-5472.CAN-13-2182.PubMed

85.

Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X, et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules. 2013;19:159–76. doi:10.3390/molecules19010159.PubMed

86.

Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, et al. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl). 2012;90:1121–32. doi:10.1007/s00109-012-0885-0.

87.

Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V, Baluchamy S. E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol Cell Biochem. 2014;390:93–100. doi:10.1007/s11010-014-1960-3.PubMed

88.

Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 2007;26:775–80. doi:10.1016/j.molcel.2007.06.001.PubMed

89.

Banks D, Wu M, Higa LA, Gavrilova N, Quan J, Ye T, et al. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle. 2014;5:1719–29. doi:10.4161/cc.5.15.3150.

90.

Mendoza M, Mandani G, Momand J. The MDM2 gene family. Biomol Concepts. 2014;5:9–19. doi:10.1515/bmc-2013-0027.PubMedPubMedCentral

91.

Nag A, Bagchi S, Raychaudhuri P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 2004;64:8152–5. doi:10.1158/0008-5472.CAN-04-2598.PubMed

92.

Shen W, Hu P, Cao JQ, Liu XX, Shao JH. MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and risk of oesophageal or gastric cancer: meta-analysis of 15 studies. J Int Med Res. 2014;42:1065–76. doi:10.1177/0300060514527910.PubMed

93.

Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, et al. High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int J Biol Sci. 2012;8:1168–77. doi:10.7150/ijbs.4778.PubMedPubMedCentral

94.

Sawada G, Ueo H, Matsumura T, Uchi R, Ishibashi M, Mima K, et al. Loss of COP1 expression determines poor prognosis in patients with gastric cancer. Oncol Rep. 2013;30:1971–5. doi:10.3892/or.2013.2664.PubMed

95.

Jackson PK. Regulating microtubules and genome stability via the CUL7/3M syndrome complex and CUL9. Mol Cell. 2014;54:713–5. doi:10.1016/j.molcel.2014.05.024.PubMed

96.

Guo H, Wu F, Wang Y, Yan C, Su W. Overexpressed ubiquitin ligase Cullin7 in breast cancer promotes cell proliferation and invasion via down-regulating p53. Biochem Biophys Res Commun. 2014;450:1370–6. doi:10.1016/j.bbrc.2014.06.134.PubMed

97.

Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant PJ, Tsai SC, et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell. 2008;30:403–14. doi:10.1016/j.molcel.2008.03.009.PubMedPubMedCentral

98.

Kuo KL, Ho IL, Shih TH, Wu JT, Lin WC, Tsai YC, et al. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015;363:127–36. doi:10.1016/j.canlet.2015.01.015.PubMed

99.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6. doi:10.1038/nature07884.PubMed

100.

Arias EE, Walter JC. Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts. Genes Dev. 2005;19:114–26. doi:10.1101/gad.1255805.PubMedPubMedCentral

101.

Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem. 2003;278:30854–8. doi:10.1074/jbc.C300251200.PubMed

102.

Abbas T, Mueller AC, Shibata E, Keaton M, Rossi M, Dutta A. CRL1-FBXO11 promotes Cdt2 ubiquitination and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell. 2013;49:1147–58. doi:10.1016/j.molcel.2013.02.003.PubMedPubMedCentral

Title: The role of cullin proteins in gastric cancer
Authors: Peng Chen
Guo-Dong Yao
Publication date: 01-01-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4154-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy

Association between x-ray repair cross-complementing group 3 (XRCC3) genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population

The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment

Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer

RETRACTED ARTICLE: The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas

MGMT testing allows for personalised therapy in the temozolomide era

Keynote webinar | Spotlight on antibody–drug conjugates in cancer